The June 1 oral presentation of data from CONVERGE-01 study of CONV01-α will highlight antitumor activity, tolerability and emerging durability in patients whose tumors have progressed following ...
Association between chemotherapy-induced neuropathy and gabapentin exposure among adults receiving chemotherapy: A National Inpatient Sample study (2017-2021). This is an ASCO Meeting Abstract from ...
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an ...
Petros Grivas, MD, PhD, expresses great enthusiasm for the 2025 ASCO Annual Meeting, highlighting its wealth of clinical trial data, educational sessions, and real-world insights. He is particularly ...
The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial ...
For patients with metastatic prostate cancer who have exhausted initial or first-line treatments like hormone therapy (also called androgen deprivation therapy or ADT) and chemotherapy, a promising ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.
Radioligand therapy has irrevocably changed oncology, proving we can map biology and strike cancer cells with unprecedented precision. Research suggests that up to 80% of cancers could potentially be ...
LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new Companies to Watch report, Radioligand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results